In summary, the analysis of recent studies promotes the use of PARP inhibitors as a new therapeutic strategy for CRPC tailored to the genomic characteristics of the tumor or the specific expression of proteins involved in HR DNA repair mechanisms. The gene discussed is PARP1; the disease is neoplasm.